Viemed Healthcare Q3 2026: Margins Expand Even as EPS Misses

As seen on the 24/7 Wall St. homepage on November 4, 2026.

VMD Viemed Healthcare
Q3 2026
EPS
$0.11
est $0.12 -10.8%
Revenue
$81M
est $81M -0.1%

Adjusted EBITDA margin widened to 21.1% from 17.6% a year ago as earlier-2026 spending converted to operating leverage, even with both lines missing estimates. Management raised the floor of full-year revenue guidance to $316 million and authorized a buyback covering up to 5% of shares.

Continue ReadingShow less

Viemed Healthcare reported Q3 2026 revenue of $80.67 million, up 12.2% year over year, narrowly missing expectations against the $80.78 million consensus. GAAP earnings per share of $0.11 also came in missing expectations versus the $0.12 estimate, continuing a streak of headline shortfalls that has run since Q1 2026.

Adjusted EBITDA margin expanded to 21.1% from 17.6% a year earlier, with CEO Casey Hoyt crediting operating leverage from investments made earlier in the year. Net income attributable to Viemed climbed 32% year over year, and operating income rose over the same period.

PAP therapy patients grew 37.5% year over year, while ventilator rental revenue, the company's largest single line, rose 7.4%. That divergence reflects Viemed's push to diversify beyond its ventilator base into sleep, women's health, and equipment sales, all of which carry a lighter capital profile than traditional respiratory rentals.

Sponsored

Management raised the floor of its full-year 2026 revenue guidance to $316 million, while narrowing the adjusted EBITDA range and lowering its net capital expenditure outlook, citing a growing mix of less capital-intensive service lines. The board authorized a new share repurchase program covering up to 5% of shares outstanding, the fourth such program, and the company repurchased shares in the quarter.

The upper end of adjusted EBITDA guidance was trimmed to $66 million, and free cash flow fell sharply year over year as capital expenditures rose. Period-end ventilator patients dipped sequentially, a small but notable softening in the core legacy product line. Medicare accounts for 34% of revenue, leaving Viemed exposed to shifts in reimbursement policy or payor audit cycles.

Mentioned: VMD